Is Blood a Good Journal? Impact Factor, Scope, and Submission Guide

Blood operates as a community journal, and this is the single most important thing to understand about its editorial model.

Unlike generalist journals (Nature Medicine, NEJM, Lancet) that publish only the broadest-impact papers, Blood has dedicated editorial pathways for every major hematology subspecialty. There are associate editors and reviewer pools for:

• Hematologic malignancies (leukemia, lymphoma, myeloma)
• Thrombosis and hemostasis
• Red cell biology (sickle cell, thalassemia, iron disorders)
• Hematopoietic stem cell transplantation
• Transfusion medicine and coagulation
• Platelet biology and bone marrow failure

This means a landmark thrombosis paper and a landmark red cell paper both have real paths to acceptance - even though they would never compete with each other at Nature Medicine. The community model is why Blood can maintain an IF of 21.0 while covering the full breadth of hematology. Each subspecialty's best work finds a home.

The practical consequence for authors: your paper does not need to be "broadly impactful across all of medicine" to fit Blood. It needs to be excellent hematology that matters to hematologists. That is a meaningfully different bar.

Blood charges no article processing charge. In a field where OA APCs at comparable journals run $3,000-$11,000, this is a real financial advantage. ASH membership and subscriptions fund the journal, keeping it free for authors.

This matters especially for researchers from institutions without large OA funds, early-career investigators, and groups in low-resource settings. The cost barrier is zero.

Blood's highest-impact papers typically:

1. State the hematologic question clearly in the first paragraph - not "we studied gene X" but "why do patients with condition Y develop complication Z"
2. Connect mechanism to clinical relevance: even basic-science Blood papers anchor their findings to disease understanding or therapeutic implications
3. Use multiple evidence layers: human patient data + animal model + mechanistic dissection, or clinical trial + biomarker + functional validation
4. Benchmark against the field: explicit comparison to existing therapies, competing models, or prior findings in the literature
5. Write for the ASH community: the abstract and discussion assume a hematologist audience, not a general biomedical one

If your paper is competitive but not quite Blood-level, Blood Advances (IF ~7.0, also ASH, also $0 APC) is the natural next step. Many Blood rejections receive a transfer offer to Blood Advances with existing reviews. This is not a consolation prize - it is a well-read ASH journal with strong indexing. Submitting to Blood with Blood Advances as a transfer fallback is a legitimate two-step strategy.

In our pre-submission review work with manuscripts targeting Blood, three patterns generate the most consistent desk rejections among the papers we analyze.

Incomplete evidence package: the story depends on future experiments. Blood's editorial guidelines ask whether the submission "presents a complete and compelling story." In our review work, the most common failure is manuscripts that are one validation cohort, one in vivo experiment, or one functional assay short of completion. The writing is strong, the hypothesis is interesting, and the preliminary data are encouraging, but the evidence package cannot sustain the central claim without a follow-up study. Blood editors identify this gap and return the paper. If the mechanistic loop is not closed, strengthen the package before submitting to Blood and consider Blood Advances in the interim.

Disease-level framing missing from mechanistic work. We observe a recurring pattern in basic hematology manuscripts: papers with excellent molecular or cellular data that never anchor to a disease state or therapeutic implication. Blood is not a basic cell biology journal. Even mechanistic papers are expected to connect to blood disease biology explicitly. Papers that characterize hematopoietic mechanisms without stating what the finding means for leukemia, thrombosis, anemia, or another clinically relevant hematologic condition consistently receive feedback about "clinical relevance" or "broader impact" and are returned.

Single subspecialty relevance without bridging significance. A persistent failure mode: papers that are excellent within one narrow hematology subspecialty but do not articulate why the finding matters to hematologists more broadly. Blood's community model means it receives excellent work from every subspecialty, but the editorial team still asks whether a paper advances the hematology field rather than just one niche. In our analysis, authors who frame their platelet, coagulation, or red cell findings entirely within subspecialty language without one sentence connecting to broader hematology consistently receive desk rejections citing "fit" rather than quality.

SciRev author-reported data confirms Blood's 3-5 week median to first decision for papers that clear the editorial screen. A Blood clinical scope check can assess whether your evidence package and disease-level framing meet Blood's editorial standards.